Form 8-K Cure Pharmaceutical Hold For: Dec 08
5 min readNews and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2020
|
CURE PHARMACEUTICAL HOLDING CORP. |
|
(Exact name of registrant as specified in its charter) |
|
Delaware |
333-204857 |
37-1765151 |
||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
1620 Beacon Place
Oxnard, California 93033
(Address of principal executive offices) (Zip Code)
(805) 824-0410
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events.
On December 8, 2020, CURE Pharmaceutical Holding Corp. (the “Company”) issued a press release announcing that its wholly owned subsidiary, The Sera Labs, Inc., has signed Oscar, Golden Globe and Emmy Award-winning Nicole Kidman as its brand’s first-ever strategic business partner and global brand ambassador for its topical products.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CURE PHARMACEUTICAL HOLDING CORP. |
|
|
|
|
|
|
|
|
Dated: December 9, 2020 |
By: |
/s/ Robert Davidson |
|
|
|
|
Robert Davidson |
|
|
|
|
Chief Executive Officer |
|
EXHIBIT 99.1
NICOLE KIDMAN PARTNERS WITH SERALABS A CURE PHARMACEUTICAL
COMPANY AS A STRATEGIC BUSINESS PARTNER AND GLOBAL BRAND AMBASSADOR
SeraLabs is a Leading CBD Health, Wellness & Beauty Company
Kidman’s partnership is exclusively with Sera Labs Topicals
Los Angeles & Oxnard, CA – December 8, 2020 – CURE Pharmaceutical Holdings (OTCQB: CURR) wholly owned subsidiary The Sera Labs, Inc., has enlisted Oscar, Golden Globe and Emmy Award-winning Nicole Kidman as the brand’s first-ever strategic business partner and global brand ambassador for their topical products. In addition to being the face of the brand, Kidman will play an integral role in the strategic direction of product development and messaging.
“We could not be more excited by Nicole’s decision to join our team,” says Nancy Duitch, SeraLabs CEO and CURE Pharmaceutical Chief Strategic Officer. “We wanted to work with someone who genuinely cares about growing the business as much as we do. A person just looking to lend their name was never going to work for us. She is savvy, forward thinking and embodies our brand values.”
Kidman became a proponent of the benefits of topical CBD when she experimented with it on an ankle injury last summer. She will bring her vast experience of the beauty sector to help SeraLabs boost its multi-channel distribution efforts and sales for its anti-aging skincare line, Seratopical® and topical ultra-hydrating and pain relief body creams and serums. The deal includes nine current SeraLabs topical products with an additional three products set to launch in 2021 where Kidman will be key in development.
“The partnership with SeraLabs was an easy decision for me,” states Kidman, SeraLabs Strategic Partner and Global Brand Ambassador. “With my injury last year, I experienced the benefit of CBD wellness products firsthand. I believe these products are a vital solution in health and wellness and Nancy and SeraLabs are a company I believe in. Joining them in this partnership is something I am very excited about!”
SeraLabs was founded in 2018 and is a global leader in the health, wellness, and beauty sectors. CURE Pharmaceutical Holdings which acquired SeraLabs in 2020 is focused on the innovation of pharmaceutical technology, wellness products and drug delivery. “The growth and global interest of our newest acquisition SeraLabs has been tremendous over the past few months,” said CURE Pharmaceutical CEO, Rob Davidson. “Nicole will undoubtedly help SeraLabs reach more consumers than ever before and grow our revenue exponentially over the next few years.”
SeraLabs can be found online and in national and regional store chains.
About SeraLabs
SeraLabs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. SeraLabs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names SeraRelief™, Seratopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. SeraLabs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, SeraLabs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: www.Seratopical.com and follow us on Instagram at @seratopical, or on Facebook or contact: [email protected]
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Media Contacts:
Monica M. Jaramillo, LABEL the Agency, [email protected], 424.273.8675,
Investor and Corporate Relations, Kathryn Brown, [email protected], 858.264.6600
